SavedAdd your journal

Journals / Medicine Science / 2017 / Cilt: 6 - Sayı: 3

Adipocytokine levels in benign prostate hyperplasia and prostate cancer patients

GÖKHAN TEMELTAŞ
FUNDA KOSOVA
TALHA MÜEZZİNOĞLU
Zeki ARI
Pages
418–423
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Therefore, similar studies should be considered with a greater number of patients at different stages

📌 3 Key Takeaways

🎯
Objective & Hypothesis:The occurrence of prostate cancer in men is one of the most common types of cancer.
📊
Key Findings & Data:The study was conducted between September 2012 and April 2013 at the Department of Medical Biochemistry and the Department of Urology.
💡
Conclusion & Impact:Therefore, similar studies should be considered with a greater number of patients at different stages
🔬Design:Research Article
📍Scope:2012 Verileri
⚙️Variables:Domain Parameters

Abstract

The occurrence of prostate cancer in men is one of the most common types of cancer. Recent studies have found important links between cancer and adipocytokines. Adipocytokines are thought to be factors in the occurrence of a variety of diseases. In addition, adipocytokines studies in cancer patients have shown that these hormones may have an effect in the formation of cancer. The objective of this study was to evaluate the relationship between adiponectin, resistin, and leptin levels in BHP and prostate cancer patients. The study was conducted between September 2012 and April 2013 at the Department of Medical Biochemistry and the Department of Urology. Blood samples were collected from 20 people in the same age range who had been diagnosed by examination and biopsy as having BHP (benign prostatic patients) and prostate cancer patients who had not been operated on. Leptin, adiponectin, resistin, and human serum levels were measured using ELISA kit. In the prostate cancer group, serum adiponectin and resistin levels were significantly lower than in the BHP group. However, serum leptin levels in the prostate cancer group were not significantly different from those in the BHP group. This information and our own findings show that adiponectin and resistin, which are from the adipocytokine family, may play an important role in the progression of prostate cancer, and thus it may be possible to use them as diagnostic markers. Therefore, similar studies should be considered with a greater number of patients at different stages

🔖

Cite This Article

TEMELTAŞ, G., KOSOVA, F., MÜEZZİNOĞLU, T., ARI, Z. (2017). Adipocytokine levels in benign prostate hyperplasia and prostate cancer patients. Medicine Science, Cilt: 6 - Sayı: 3, 418–423. https://ajindex.com/articles/277398

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (12)

  1. Akdaş A, Çevik I. BHP- Benign Prostat Hiperplazisi. Hekimler Yayın Birliği. 1996;27-37
  2. Rcquıer D. Respiration uncoupling and metabolism in the control of energy expenditure. Proc Nutr Soc. 2005;64(1):47-2
  3. Fukuhara A, Matsuda M, Nishizawa M, Segawa K, Tanaka M, Kishimoto K, Matsuki Y, Murakami M, Ichisaka T, Murakami H, Watanabe E, Takagi T, Akiyoshi M, Ohtsubo T, Kihara S, Yamashita S, Makishima M, Funahashi T, Yamanaka S, Hiramatsu R, Matsuzawa Y, Shimomura I. Visfatin: a protein secreted by visceral fat that mimics the effects of insulin. Science. 2005;307(5708):426-30
  4. Zhao Y, Sun R, You L, Gao C, Tian Z. Expression of leptin receptors and response to leptin stimulation of human natural killer cell lines. Biochem Biophys Res Commun. 2003;300(2):247-2
  5. Caldefie-Chezet F, Poulin A, Tridon A, Sion B, Vasson MP. Leptin: a potential regulator of polymorphonuclear neutrophil bactericidal action? J Leukoc Biol. 2001;69(3):414-8
  6. Galili O, Versari D, Sattler KJ, Olson ML, Mannheim D, McConnell JP, Chade AR, Lerman LO, Lerman A. Early Experimental Obesity Is Associated with Coronary Endothelial Dysfunction and Oxidative Stress. Am J Physiol Heart Circ Physiol. 2007;292(2):904-1
  7. Koerner A, Kratzsch J, Kiess W. Adipocytokines: leptin the classical, resistin the controversical, adiponectin the promising, and more to come. Best Pract Res Clin Endocrinol Metab. 2005;19(4):525-46
  8. Maeda N, Shimomura I, Kishida K, Nishizawa H, Matsuda M, Nagaretani H, Furuyama N, Kondo H, Takahashi M, Arita Y, Komuro R, Ouchi N, Kihara S, Tochino Y, Okutomi K, Horie M, Takeda S, Aoyama T, Funahashi T, Matsuzawa Y. Diet-induced insulin resistance in mice lacking adiponectin/ACRP30. Nat Med. 2002;8(7):731-7
  9. Wasim H, Al-Daghri NM, Chetty R, McTernan PG, Barnett AH, Kumar S. Relationship of serum adiponectin and resistin to glucose intolerance and fat topography in South-Asians. Cardiovasc Diabetol. 2006;2:5-0
  10. Palomer X, Pérez A, Blanco-Vaca F. Adiponectin: a new link between obesity, insulin resistance and cardiovascular disease. Med Clin (Barc). 2005;124(10):388-5
  11. Fukuhara A, Matsuda M, Nishizawa M, Segawa K, Tanaka M, Kishimoto K, Matsuki Y, Murakami M, Ichisaka T, Murakami H, Watanabe E, Takagi T, Akiyoshi M, Ohtsubo T, Kihara S, Yamashita S, Makishima M, Funahashi T, Yamanaka S, Hiramatsu R, Matsuzawa Y, Shimomura I. Visfatin: a protein secreted by visceral fat that mimics the effects of insulin. Science. 2005;307(5708):426-0
  12. Bray Ga. The